G D Marijn Veerman
Overview
Explore the profile of G D Marijn Veerman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Pruis M, Veerman G, Hassing H, Lanser D, Paats M, van Schaik R, et al.
JACC CardioOncol
. 2023 Mar;
5(1):102-113.
PMID: 36875894
Background: Anaplastic lymphoma kinase (ALK) translocations in metastatic non-small cell lung cancer (3% to 7%) predict for response to ALK-inhibitors (eg, alectinib, first line), resulting in a 5-year survival rate...
12.
de Leeuw S, de Bruijn P, Koolen S, Dingemans A, Mathijssen R, Veerman G
J Pharm Biomed Anal
. 2023 Jan;
225:115233.
PMID: 36638566
Overall survival in metastatic lung cancer has been dramatically improved with the use of small molecule kinase inhibitors (SMKIs). Quantification of SMKI in cerebrospinal fluid (CSF) can be used to...
13.
Veerman G, Hurkmans D, Paats M, Oomen-de Hoop E, van der Leest C, van Thiel E, et al.
Biomed Pharmacother
. 2022 Sep;
155:113695.
PMID: 36126454
Afatinib is an oral small-molecule kinase inhibitor (SMKI) approved for treatment of metastatic non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) driver mutation. Although oral administration...
14.
Agema B, Veerman G, Steendam C, Lanser D, Preijers T, van der Leest C, et al.
Ther Adv Med Oncol
. 2022 Jun;
14:17588359221103212.
PMID: 35677320
Background: Osimertinib is the cornerstone in the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer (NSCLC). Nonetheless, ±25% of patients experience severe treatment-related toxicities. Currently, it is impossible...
15.
Veerman G, van der Werff S, Koolen S, Miedema J, Oomen-de Hoop E, van der Mark S, et al.
Biomed Pharmacother
. 2022 May;
151:113101.
PMID: 35594703
Nintedanib is an oral small-molecule kinase inhibitor and first-line treatment for idiopathic pulmonary fibrosis. Nintedanib is a substrate of the drug efflux transporter ABCB1. Green tea flavonoids --especially epigallocatechin gallate...
16.
Heersche N, Veerman G, de With M, Bins S, Assaraf Y, Dingemans A, et al.
Drug Resist Updat
. 2022 Apr;
62:100832.
PMID: 35427871
Small-molecule kinase inhibitors (SMKIs) represent the cornerstone in the treatment of non-small cell lung cancer (NSCLC) patients harboring genetic driver mutations. Because of the introduction of SMKIs in the last...
17.
Steendam C, Peric R, van Walree N, Youssef M, Schramel F, Brocken P, et al.
Lung Cancer
. 2021 Aug;
160:44-49.
PMID: 34403911
Background: Earlier preclinical and phase II research showed enhanced effect of docetaxel plus intercalated erlotinib. The NVALT-18 phase III study was designed to compare docetaxel with docetaxel plus intercalated erlotinib...
18.
Veerman G, de Bruijn P, Dingemans A, Mathijssen R, Koolen S
J Pharm Biomed Anal
. 2020 Nov;
193:113733.
PMID: 33217707
Multiple small-molecule kinase inhibitors with specific molecular targets have recently been developed for the treatment of cancer. This article reports the development and validation of an ultra-performance liquid chromatography/tandem mass...
19.
Steendam C, Veerman G, Pruis M, Atmodimedjo P, Paats M, van der Leest C, et al.
Cancers (Basel)
. 2020 Nov;
12(11).
PMID: 33138052
Although epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the preferred treatment for patients with -mutated non-small cell lung cancer (NSCLC), not all patients benefit. We therefore explored the...
20.
Veerman G, van den Bent M, Paats M
Radiol Case Rep
. 2020 Oct;
15(12):2668-2671.
PMID: 33101563
A 52-year-old woman presented to the emergency department with several days of progressive dyspnoea and thoracic pain. Her medical history included a (recurrent) anaplastic meningioma, for which she was treated...